August 08, 2025

INSL5 Rise Tied to Diarrhoea Severity, Treatment

Circulating Insulin-like peptide 5 concentrations may reflect colonic exposure to bile acids and help stratify treatment response in patients with chronic diarrhoea, including those with irritable bowel syndrome with diarrhoea and bile acid diarrhoea.

Conexiant

August 06, 2025

Bimekizumab Sustains Psoriasis Response for 3 Years

A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.

Conexiant

July 11, 2025

Patients With Sludge Pancreatitis Have Fewer Complications

An international cohort study found that patients with sludge- or microlithiasis-induced acute pancreatitis had significantly fewer long-term complications than those with gallstone-related pancreatitis.

Conexiant

July 30, 2025

Ondansetron Cuts 7-Day Gastroenteritis Severity in Children, Study Finds

Home use of ondansetron following emergency care for pediatric gastroenteritis lowers the risk of moderate-to-severe illness within 7 days, without increasing serious adverse events.

Conexiant

July 29, 2025

Postpartum Pelvic Floor Disorders Often Overlooked, Review Finds

Emerging diagnostic tools such as dynamic ultrasound and anorectal manometry offer clinicians improved evaluation of postpartum pelvic floor disorders, yet standardized screening protocols remain limited.

Conexiant

July 21, 2025

Guselkumab Tops Ustekinumab in Crohns

In a 48-week analysis of 1021 adults with moderate-to-severe Crohn’s disease, guselkumab outperformed placebo and ustekinumab in endoscopic and composite clinical endpoints.

Conexiant

July 16, 2025

New Guidelines Target Preventive Gaps in Inflammatory Bowel Disease

New clinical recommendations detail updated vaccination and screening protocols to reduce infection and cancer risks in adults with inflammatory bowel disease, particularly those on immune-modifying therapies.

Conexiant

July 10, 2025

1 in 4 U.S. Infants Missing Bifidobacterium: Study

Babies who lacked this key gut bacteria were at an increased risk of eczema, allergies, and asthma by age 2.

Conexiant

July 10, 2025

Tramadol Carries Lowest Constipation Risk Among Opioids

The UK hospital study of over 80,000 patients found that certain opioids, including morphine and oxycodone, carried a higher risk of severe constipation compared with others.

Conexiant